



**Editor-in-Chief**  
Pedro T Ramirez (USA)

**Associate Editors**  
Antonio Gonzalez (Spain)  
Anna Fagotti (Italy)  
Michael Frumovitz (USA)  
Rene Pareja (Colombia)  
Anuja Jhingran (USA)

**Video Editor**  
Luis Chiva (Spain)

**Social Media Editor**  
Ane Gerda Zahl Eriksson (Norway)

**Managing Editor**  
Lindsey Struckmeyer (USA)

**Editorial Office**  
*International Journal of Gynecological Cancer*, BMJ Journals  
Two Hudson Square, 3rd Floor,  
Hoboken, NJ 07030 USA  
E: [ijgc@jmeditorial.com](mailto:ijgc@jmeditorial.com)

**Production Editor**  
Michaela Joseph  
E: [production.ijgc@bmj.com](mailto:production.ijgc@bmj.com)

**Customer support**  
For general queries and support with  
existing and new subscriptions:  
W: [support.bmj.com](mailto:support.bmj.com)  
T: +44 (0)20 7111 1105  
E: [support@bmj.com](mailto:support@bmj.com)

Self-archiving and permissions  
W: [bmj.com/company/products-services/rights-and-licensing/](http://bmj.com/company/products-services/rights-and-licensing/)  
E: [bmj.permissions@bmj.com](mailto:bmj.permissions@bmj.com)

**Disclaimer:** The Editor of *International Journal of Gynecological Cancer* has been granted editorial freedom and *International Journal of Gynecological Cancer* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *International Journal of Gynecological Cancer* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *International Journal of Gynecological Cancer* does not imply endorsement. Neither *International Gynecologic Cancer Society* and *European Society of Gynaecological Oncology* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *International Journal of Gynecological Cancer* (except for liability which cannot be legally excluded).

**Copyright:** © 2020 IGCS and ESGO. All rights reserved; no part of this publication may be reproduced in any form without permission.

The *International Journal of Gynecological Cancer* (IJGC) is published by BMJ Publishing Group Ltd and typeset by Exeter Premedia Services Private Limited, Chennai, India.

## Lead articles

- 1089** Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium  
*D Nasioudis, A G Roy, E M Ko, L Cory, R L Giuntoli II, A F Haggerty, S H Kim, M A Morgan, N A Latif*

## Editorial

- 1095** Getting *serious* about serous endometrial cancer: should we give chemotherapy in non-invasive cases?  
*J Mueller, V Makker*

## Society statement

- 1097** European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID-19 pandemic  
*A Ciavattini, G Delli Carpini, L Giannella, M Arbyn, M Kyrgiou, E A Joura, J Sehouli, X Carcopino, C W Redman, P Nieminen, M Cruickshank, M Gultekin*

## COVID-19

- 1101** Change in practice in gynecologic oncology during the COVID-19 pandemic: a social media survey  
*F Martinelli, A Garbi*
- 1108** COVID-19: gynecologic cancer surgery at a single center in Madrid  
*J de Santiago, C Yelo, M F Chereguini, A Conde, J Galipienzo, D Salvatierra, M Linero, S Alonso*

## Vulvar Cancer

- 1113** Complication rates and lymph node count between two different skin incisions at time of inguino-femoral lymph node dissection in vulvar cancer  
*S E F Jones, K Lim, J Davies, R Howells, R Jones, A Sharma*

- 1118** Vulvar sarcoma outcomes by histologic subtype: a Surveillance, Epidemiology, and End Results (SEER) database review  
*S Johnson, M Renz, L Wheeler, E Diver, O Dorigo, B Litkouhi, K Behbakht, B Howitt, A Karam*

## Preinvasive Disease

- 1124** A sustainable model for raising colposcopy expertise in low-to-middle-income countries  
*I Ismail-Pratt, E J J Mayeaux, Q V Ngo, J Lee, J Ng*

## Cervical Cancer

- 1129** Surveillance patterns of cervical cancer patients treated with conization alone  
*S Pedra Nobre, V Mazina, A Iasonos, Q C Zhou, Y Sonoda, G Gardner, K Long-Roche, M M Leitao, N R Abu-Rustum, J J Mueller*
- 1136** Tailored radical hysterectomy for locally advanced cervical cancer  
*N Sakuragi, M Kaneuchi, T Kato, C Shimada, Y Todo, K Ihira, A Nozaki, T Umazume, Y Konno, T Mitamura, N Kobayashi, G Murakami, H Watari*
- 1143** Comparison of laparoscopic versus open radical hysterectomy in patients with early-stage cervical cancer: a multicenter study in China  
*T w yi Hu, Y Huang, N Li, D Nie, Z Li*
- 1151** Tumor microbial diversity and compositional differences among women in Botswana with high-grade cervical dysplasia and cervical cancer  
*T T Sims, G W G Biegert, D Ramogola-Masire, K Ngoni, T Solley, M S Ning, M B El Alam, M Mezzari, J Petrosino, N M Zetola, K M Schmeler, L E Colbert, A H Klopp, S Grover*

- 1157** Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer  
*J Contreras, A Srivastava, A Chundury, J K Schwarz, S Markovina, P H Thaker, L S Massad, D G Mutch, M A Powell, P W Grigsby, A J Lin*

## Uterine Cancer

- 1162** Comparison of minimally invasive versus open surgery in the treatment of endometrial carcinosarcoma



*S Pedra Nobre, J J Mueller, G J Gardner, K Long Roche, C L Brown, R A Soslow, K M Alektiar, Y Sonoda, V A Broach, E L Jewell, O Zivanovic, D S Chi, N R Abu-Rustum, M M Leitao, Jr.*

- 1169** Role of adjuvant therapy in stage IIIC2 endometrial cancer

*G Bogani, S Cappuccio, J Casarin, D M M Narasimhulu, W A Cilby, G E Glaser, A L Weaver, M E McGree, G L Keeney, J Weroha, I A Petersen, A Mariani*

- 1177** Patient-initiated follow-up after treatment for low risk endometrial cancer: a prospective audit of outcomes and cost benefits

*S Coleridge, J Morrison*

## Ovarian Cancer

- 1183** Hematologic changes after splenectomy for ovarian cancer debulking surgery, and association with infection and venous thromboembolism

*O T Filippova, S W Kim, R A Cowan, A J Chi, A Iasonos, Q C Zhou, V Broach, O Zivanovic, K Long Roche, Y Sonoda, G Gardner, D S Chi*

- 1189** Robotic-assisted laparoscopic splenectomy for recurrent ovarian cancer



*T A Paterniti, S Ahmad, R W Holloway*

- 1195** National trends in bowel and upper abdominal procedures in ovarian cancer surgery

*J A Dottino, W He, C C Sun, H Zhao, S Fu, J A Rauh-Hain, R S Suidan, K H Lu, S H Giordano, L A Meyer*

## Surgery

- 1203** Postoperative complications of epidural analgesia at hysterectomy for gynecologic malignancies: an analysis of the National Surgical Quality Improvement Program



*S A Ackroyd, E Hernandez, M E Roberts, C Chu, S Rubin, G Mantia-Smaldone, K Houck*

- 1210** Modification of Dargent's radical vaginal trachelectomy to facilitate ureteral dissection: description of technique

*A Plaikner, A Jacob, K Siegler, A Schneider, V Ragoesch, J Barinoff, C Kohler*

## Reviews

- 1215** Measurement of tumor size in early cervical cancer: an ever-evolving paradigm



*G Salvo, D Odetto, M C Saez Perrotta, F Noll, M Perrotta, R Pareja, A Wernicke, P T Ramirez*

- 1224** Exploiting replicative stress in gynecological cancers as a therapeutic strategy



*N YL Ngoi, V Sundararajan, D SP Tan*

## Clinical trial

- 1239** A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)



*N YL Ngoi, V Heong, S Ow, W Y Chay, H S Kim, C H Choi, G Goss, J C Goh, B C Tai, D GZ Lim, N Kaliaperumal, V B Au, J E Connolly, J-W Kim, M Friedlander, K Kim, D SP Tan*

## Case study

- 1243** Intracardiac intravenous leiomyomatosis: diagnosis and management

*I Stiliadi, J Paianidi, V Bokhian, J Andreeva, A Shevchuk, P T Ramirez*

## Corners of the world

- 1248** HPV vaccination: a Tunisian challenge

*M A Ferjaoui*

## Video articles

- 1249** Creatsas modified vaginoplasty as reconstructive treatment of vaginal stenosis due to vaginal or pelvic radiotherapy

*S Vazquez, P Padilla-Iserte, T Marina, V Lago, L Matute, S Domingo*

- 1250** Persistent postoperative ascites successfully identified and treated with laparoscopic indocyanine green fluorescence



*R Fernandes, C Anton, A Lopes, A S e Silva, E Leblanc, U Ribeiro Jr, J P Carvalho*

- 1252** Adaptations and modifications in the technique of laparoscopic hysterectomy with bilateral adnexectomy in the time of COVID-19

*J M Saadi, J P S Cortez, F Noll, J P Brown, L Bolaño*

- 1253** Ovarian sparing cystectomy for borderline serous tumor through vNOTES (vaginal Natural Orifices Transluminal Endoscopic Surgery)

*L Badiglian-Filho, E M Fukazawa, C Faloppa, G Baiocchi*

## Commentaries

- 1255** COVID 19 vaccination lessons from Japanese anti-HPV vaccination lobby
- K Fujiwara, M A Quinn*
- 1256** Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020
- A Madariaga, L Bonilla, M McMullen, A M Oza, S Lheureux*
- 1258** Two viral infections in Japan
- K Fujiwara, M A Quinn, R L Coleman, R Angioli*

## Letters

- 1260** Is there a place for lower limb lymphedema prevention after cervical cancer treatment?
- J M T Baiocchi, G Baiocchi, A Bergmann*

- 1261** Reply to: Is there a place for lower limb lymphedema prevention after cervical cancer treatment?
- Y Ding, X Wang, H Cai*

- 1263** Letter to the Editor on Jones SEF, Lim K, Davies J, et al. Complication rates and lymph node count between two different skin incisions at time of inguino-femoral lymph node dissection in vulvar cancer
- J P Carvalho, A Ribeiro Dias Jr, F M Carvalho*

- 1264** Response to a letter from Jesus Paula Carvalho and team regarding the Jones et al article on 'Complication rates and lymph node count between two different skin incisions at time of inguino-femoral lymph node dissection in vulvar cancer'
- S E F Jones, R Howells, A Sharma*

## Miscellaneous

- 1265** Correction: *External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis*
- 1266** Correction: *Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer*
- 1267** Correction: *Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study*